The aim of the project was to find effective treatment for severe mental disorders and identify risk factors for disease. This has been done by integrating ongoing Norwegian studies in schizophrenia and bipolar disorder.
The project is based on a collaboration between all health regions in Norway, and includes clinical and genetic research questions. We have completed data collection, and worked on data analysis. Intervention studies have been completed the inclusion of patients.
We have conducted large scale analyzes of genetic factors from the central analysis group. We have worked a lot with reporting of publication of results last year.
The partners have published a series of works based on people and data involved in the project.
Schizophrenia (SCZ) and bipolar disorder (BIP) are recognized as globally leading causes of morbidity. However, the disease mechanisms are still unknown, and the treatment needs to be improved. The disorders are regarded as complex genetic but most of the high heritability is not yet explained. The overall aim of the current project is to identify patient and treatment determinants of outcome in severe mental disorders trough integrating ongoing Norwegian research initiatives in SCZ and BIP. We will do this with a translational approach, comprising clinical and genetic sub-projects, in close collaboration with all health regions in Norway. It is based on the strongest national research groups in this field who are already participating in several nation al collaborations together with international partners. We will include patients receiving standardized treatment in the Norwegian health care system, and follow the patients over time, integrated with RCT intervention trials, which will provide an enormo us repository and database for future studies. We will take advantage of our established collaborative networks and existing cohort, where all participants are assessed with the same clinical, cognitive, biochemical and imaging protocols based on current state-of-the-art methods. We will expand the common clinical protocol with diagnostic instruments easier to use in clinical settings (1), study the effect of treatment delays on the early course and outcome in BIP (2), and the mechanism underlying metab olic disturbances associated with antipsychotics (3) and the use of cognitive behavior therapy to counter sleep disturbances and thus new episodes in BIP (4), and finally we will combine all collected DNA and clinical information, for large scale search o f the hidden heritability (5). In addition to novel new knowledge, the present project will strengthen the newly established national collaborative network and psychiatric research in each health region.